Implementation Science Using Proctor's Framework and an Adaptation of the Multiphase Optimization Strategy: Optimizing a Financial Incentive Intervention for HIV Treatment Adherence in Tanzania.


Journal

Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005

Informations de publication

Date de publication:
12 2019
Historique:
entrez: 26 11 2019
pubmed: 26 11 2019
medline: 6 6 2020
Statut: ppublish

Résumé

Ambitious targets have been set to end the HIV epidemic by 2030. Such targets assume that tools to end HIV exist and are successfully being deployed across populations, albeit unequally. Implementation science approaches are needed to understand the drivers of disparities and how to bring effective interventions to those most in need. We describe a hybrid implementation science approach, adapting a strategy to facilitate retention and viral suppression (VS) among people living with HIV/AIDS in Tanzania. We used Proctor framework and the multiphase optimization strategy to optimize a cash transfer to improve antiretroviral therapy adherence and VS among people living with HIV/AIDS in Tanzania. This involved 3 trials. The first trial tested the efficacy of cash and food assistance compared with the standard of care in improving antiretroviral therapy adherence among treatment initiators. Cash transfers were superior to the standard of care and noninferior, less expensive, and logistically simpler to implement compared with food. The second trial is dose-finding: identifying the optimal amount of cash for a 20% improvement in VS at 6 months. Before this, components were simplified to maximize reach, align with local policies, and reduce staff time. We assessed implementation science constructs to understand barriers to uptake and sustainability. Trial 3 is a cluster randomized controlled trial, testing the effectiveness of the optimized intervention in multiple settings. Our process illustrates the utility of applying multiple implementation science frameworks to arrive at an optimal implementation strategy to bridge the know-do gap with data to show efficacy and maximum potential for scalability and sustainability.

Sections du résumé

BACKGROUND
Ambitious targets have been set to end the HIV epidemic by 2030. Such targets assume that tools to end HIV exist and are successfully being deployed across populations, albeit unequally. Implementation science approaches are needed to understand the drivers of disparities and how to bring effective interventions to those most in need. We describe a hybrid implementation science approach, adapting a strategy to facilitate retention and viral suppression (VS) among people living with HIV/AIDS in Tanzania.
METHODS/DESIGN
We used Proctor framework and the multiphase optimization strategy to optimize a cash transfer to improve antiretroviral therapy adherence and VS among people living with HIV/AIDS in Tanzania. This involved 3 trials. The first trial tested the efficacy of cash and food assistance compared with the standard of care in improving antiretroviral therapy adherence among treatment initiators. Cash transfers were superior to the standard of care and noninferior, less expensive, and logistically simpler to implement compared with food. The second trial is dose-finding: identifying the optimal amount of cash for a 20% improvement in VS at 6 months. Before this, components were simplified to maximize reach, align with local policies, and reduce staff time. We assessed implementation science constructs to understand barriers to uptake and sustainability. Trial 3 is a cluster randomized controlled trial, testing the effectiveness of the optimized intervention in multiple settings.
DISCUSSION/IMPLICATIONS
Our process illustrates the utility of applying multiple implementation science frameworks to arrive at an optimal implementation strategy to bridge the know-do gap with data to show efficacy and maximum potential for scalability and sustainability.

Identifiants

pubmed: 31764271
doi: 10.1097/QAI.0000000000002196
pii: 00126334-201912003-00022
pmc: PMC6880807
mid: NIHMS1540168
doi:

Substances chimiques

Anti-HIV Agents 0
Anti-Retroviral Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

S332-S338

Subventions

Organisme : NIMH NIH HHS
ID : K01 MH094246
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH112432
Pays : United States
Organisme : FIC NIH HHS
ID : R25 TW009338
Pays : United States
Organisme : PEPFAR
Pays : United States

Références

Addict Behav. 2002 Nov-Dec;27(6):989-93
pubmed: 12369480
Lancet Glob Health. 2013 Dec;1(6):e362-70
pubmed: 25104601
Lancet. 2012 Apr 7;379(9823):1320-9
pubmed: 22341825
Acad Emerg Med. 2005 Jul;12(7):617-21
pubmed: 15995093
PLoS One. 2014 Jan 15;9(1):e85473
pubmed: 24454875
Clin Infect Dis. 2011 Feb 15;52(4):493-506
pubmed: 21245156
BMJ Open. 2012 Feb 08;2:e000747
pubmed: 22318666
J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):e56-63
pubmed: 23403860
Adm Policy Ment Health. 2009 Jan;36(1):24-34
pubmed: 19104929
Annu Rev Public Health. 2017 Mar 20;38:1-22
pubmed: 28384085
AIDS Behav. 2013 Sep;17(7):2283-92
pubmed: 23370833
PLoS One. 2013;8(2):e56307
pubmed: 23509605
Implement Sci. 2017 Aug 8;12(1):102
pubmed: 28784155
AIDS Res Hum Retroviruses. 2008 Aug;24(8):1031-5
pubmed: 18724803
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
BMC Public Health. 2017 May 4;17(1):383
pubmed: 28472928
Am Econ Rev. 2008 Dec 1;98(5):1829-1863
pubmed: 21687831
Med Care. 2012 Mar;50(3):217-26
pubmed: 22310560
AIDS Behav. 2014 Oct;18 Suppl 5:S505-15
pubmed: 23842717
Am J Prev Med. 2007 May;32(5 Suppl):S112-8
pubmed: 17466815
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
Health Psychol Rev. 2015;9(3):277-95
pubmed: 25207647
Am J Public Health. 1999 Sep;89(9):1322-7
pubmed: 10474547
J Acquir Immune Defic Syndr. 2015 May 1;69(1):98-108
pubmed: 25942461
Annu Rev Clin Psychol. 2012;8:21-48
pubmed: 22224838
AIDS Behav. 2015 Aug;19(8):1510-26
pubmed: 25096896
Adm Policy Ment Health. 2011 Mar;38(2):65-76
pubmed: 20957426
JMIR Mhealth Uhealth. 2018 Jan 05;6(1):e4
pubmed: 29305343
J Acquir Immune Defic Syndr. 2011 Apr;56(4):356-64
pubmed: 21191309
Ann Behav Med. 2005 Aug;30(1):65-73
pubmed: 16097907
BMC Infect Dis. 2015 Oct 28;15:490
pubmed: 26520572
Clin Trials. 2014 Jun 5;11(4):426-434
pubmed: 24902922
AIDS. 2017 Mar 27;31(6):815-825
pubmed: 28107221

Auteurs

Laura Packel (L)

Department of Epidemiology and Biostatistics, University of California, Berkeley, School of Public Health, Berkeley, CA.

Carolyn Fahey (C)

Department of Epidemiology and Biostatistics, University of California, Berkeley, School of Public Health, Berkeley, CA.

Prosper Njau (P)

Health for a Prosperous Nation, Dar es Salaam, Tanzania.
Ministry of Health, Community Development, Gender, Elderly and Children (MoHCDGEC), Dar es Salaam, Tanzania.

Sandra I McCoy (SI)

Department of Epidemiology and Biostatistics, University of California, Berkeley, School of Public Health, Berkeley, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH